These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 17363756)

  • 1. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients.
    Rosenstock J; Hollander P; Gadde KM; Sun X; Strauss R; Leung A;
    Diabetes Care; 2007 Jun; 30(6):1480-6. PubMed ID: 17363756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.
    Wilding J; Van Gaal L; Rissanen A; Vercruysse F; Fitchet M;
    Int J Obes Relat Metab Disord; 2004 Nov; 28(11):1399-410. PubMed ID: 15486569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
    Eliasson B; Gudbjörnsdottir S; Cederholm J; Liang Y; Vercruysse F; Smith U
    Int J Obes (Lond); 2007 Jul; 31(7):1140-7. PubMed ID: 17264849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Toplak H; Hamann A; Moore R; Masson E; Gorska M; Vercruysse F; Sun X; Fitchet M
    Int J Obes (Lond); 2007 Jan; 31(1):138-46. PubMed ID: 16703004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.
    Bray GA; Hollander P; Klein S; Kushner R; Levy B; Fitchet M; Perry BH
    Obes Res; 2003 Jun; 11(6):722-33. PubMed ID: 12805393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension.
    Tonstad S; Tykarski A; Weissgarten J; Ivleva A; Levy B; Kumar A; Fitchet M
    Am J Cardiol; 2005 Jul; 96(2):243-51. PubMed ID: 16018851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects.
    Astrup A; Caterson I; Zelissen P; Guy-Grand B; Carruba M; Levy B; Sun X; Fitchet M
    Obes Res; 2004 Oct; 12(10):1658-69. PubMed ID: 15536230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
    Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes.
    Stenlöf K; Rössner S; Vercruysse F; Kumar A; Fitchet M; Sjöström L;
    Diabetes Obes Metab; 2007 May; 9(3):360-8. PubMed ID: 17391164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study.
    McElroy SL; Hudson JI; Capece JA; Beyers K; Fisher AC; Rosenthal NR;
    Biol Psychiatry; 2007 May; 61(9):1039-48. PubMed ID: 17258690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
    Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
    Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.
    Winslow DH; Bowden CH; DiDonato KP; McCullough PA
    Sleep; 2012 Nov; 35(11):1529-39. PubMed ID: 23115402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
    Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
    Garvey WT; Ryan DH; Bohannon NJ; Kushner RF; Rueger M; Dvorak RV; Troupin B
    Diabetes Care; 2014 Dec; 37(12):3309-16. PubMed ID: 25249652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
    Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
    Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topiramate: a new potential pharmacological treatment for obesity.
    Astrup A; Toubro S
    Obes Res; 2004 Dec; 12 Suppl():167S-73S. PubMed ID: 15687413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.